CASI News and Press, CASI Pharmaceuticals Inc. From 03/17/20

Image source: The Motley Fool. CASI Pharmaceuticals Inc   (NASDAQ: CASI) Q4 2019 Earnings Call Mar 16, 2020 , 4:30 p.m. ET Operator Continue reading

CASI Pharmaceuticals (NASDAQ: CASI ): FY GAAP EPS of -$0.48 misses by $0.07 . More news on: CASI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

ROCKVILLE, Md. and BEIJING , March 16, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended...

Deals and Financings Alphamab Oncology, a company developing eight bispecifics for oncology, plans to stage an IPO before the end of the year on the Hong Kong Exchange that could raise up to $350 million. Alphamab Oncology is a spin out from Suzhou Alphamab. The company plans to use the proc...

The China National Medical Product Administration (NMPA) has approved CASI Pharmaceuticals' (NASDAQ: CASI ) clinical trial applications for CNCT19 (CD19 CAR-T) in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL) submitted by its p...

ROCKVILLE, Md. and BEIJING , Dec. 3, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that the China National Medical Product Adm...

CASI Pharmaceuticals (NASDAQ: CASI ): Q3 GAAP EPS of -$0.10 beats by $0.01 . More news on: CASI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

ROCKVILLE, Md. and BEIJING , Nov. 12, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, today reported financial results for the third quarter and nine m...

ROCKVILLE, Md. and BEIJING , Nov. 7, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces an exclusive distribution agreement with Ph...

Deals and Financings China Biologic Products (CBPO), a blood products company, received a $4.6 billion takeover offer from a group of six investment firms (see story ). The proposal was priced at $120 per share, a 16% premium to the previous close. CBPO operates plasma-gathering facilities ...